ARAF and tuberculosis: Pks13 in addition to its importance as a target to develop new drugs against tuberculosis is a particularly unusual type I PKS in the sense that (i) it has an atypical domain organization with two ACP domains, (ii) it loads specifically long substrates activated in an unusual way and (iii) it has an atypical product release mode.